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cerative colitis (ASUC). The aimof this studywas todescribe this evolution in aprospective cohort.METHODS: Patients admitted for a steroid-refractory ASUC and included in a randomized trial comparing
infliximab and cyclosporine were eligible if they achieved steroid-free clinical remission at day
98. Flexible sigmoidoscopies were performed at baseline, days 7, 42 and 98. Ulcerative colitisr: IQR, interquartile range; UCEIS, Ulcer-
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Down
2021.endoscopic index of severity (UCEIS) and its sub-scores - vascular pattern, bleeding and
ulceration/erosion - were post-hoc calculated. Global endoscopic remission was defined by a
UCEIS of 0, and partial endoscopic remission by any UCEIS sub-score of 0.RESULTS: Among the 55 patients analyzed (29 infliximab and 26 cyclosporine), 49 (83%) had UCEIS ‡6 at
baseline at baseline. Partial endoscopic remission rates were higher for bleeding than for
vascular pattern and for ulcerations/erosions at day 7 (20% vs. 4% and 5% (n [ 55); p [ .004
and p[.04), for bleeding and ulceration/erosion than for vascular pattern at day 42 [63% and
65% vs. 33% (n[54); p<.001 for both] and at day 98 [78% and 92% vs. 56% (n[ 50); p[ .007
and p < .001]. Global endoscopic remission rates at day 98 were higher in patients treated with
infliximab than with cyclosporine [73% vs. 25% (n [ 26 and 24); p < .001].CONCLUSION: In steroid-refractory ASUC patients responding to a second-line medical therapy, endoscopic
remission process started with bleeding remission and was not achieved in half the patients at
day 98 for vascular pattern. Infliximab provided a higher endoscopic remission rate than
cyclosporine at day 98.Keywords: ulcerative Colitis; Cyclosporine; Infliximab; Mucosal Healing; UCEIS.Ulcerative colitis is a chronic and disabling in-flammatory bowel disease affecting the rectum
and the colon,1 characterized by unpredictable inflam-
matory flares that can be in 25% of patients a life-
threatening severe attack.2
Identification of patients having an acute severe ul-
cerative colitis is still based on the historical clinico-
biological Truelove-Witts criteria.3,4 These patients
should be emergently admitted in a dedicated unit to
receive speed-acting parenteral drugs according to a
standardized protocol with the aim to avoid salvage
colectomy.4 The medical regimen starts with intravenous
steroids, followed by infliximab or cyclosporine in case of
failure. Despite an optimal management, even in expe-
rienced centers, acute severe ulcerative colitis death rate
remains 1% in Western countries.5
The ultimate therapeutic objective in ulcerative colitis
is to achieve sustained steroid-free clinical remission
together with healing of endoscopic inflammatory le-
sions.4 Consequently, repeated endoscopic assessments
have been implemented in practice to score the severity
of endoscopic lesions to adjust the therapeutic strategy.
The 2 more frequently used endoscopic ulcerative colitis
scoring systems are the Mayo endoscopic subscore and
the more recent Ulcerative Colitis Endoscopic Index of
Severity (UCEIS) that has been built and validated on the
most reproducible inflammatory items that are vascular
pattern, bleeding, and erosions or ulcerations.6–9 Inter-
estingly, UCEIS can be used for assessing patients with
acute severe ulcerative colitis as shown by 2 retrospec-
tive cohorts.10,11
Few data are available on the evolution of acute se-
vere ulcerative colitis endoscopic lesions. Therefore, the
aim of the present study was to describe the evolution of
endoscopic lesions in a prospective cohort of patients
admitted for a steroid-refractory acute severe ulcerative
colitis and included in the CYSIF trial,12 if they responded
to a second-line medical therapy.loaded for Anonymous User (n/a) at University of He
 For personal use only. No other uses without permissMaterials and Methods
Study Design and Patients
The CYSIF trial was a European randomized, open-
label, controlled trial conducted in 23 French and
Belgian GETAID (Groupe d’Etude sur les Affections
Inflammatoires Digestives) and 6 European ECCO (Eu-
ropean Crohn and Colitis Organisation) centers,
comparing cyclosporine with infliximab in 115 patients
admitted for steroid-refractory acute severe ulcerative
colitis (EudraCT: 2006-005299-42; ClinicalTrials.gov:
NCT00542152). Patients were included from June 2007
to August 2010. Briefly, eligible patients were adults
having an acute severe ulcerative colitis defined by a
Lichtiger score >10, who were refractory to at least 0.8
mg/kg/d of intravenous methylprednisolone or equiva-
lent given for at least 5 days and who were naive for
cyclosporine, infliximab, and thiopurine except if it was
started <4 weeks before inclusion. Patients with indi-
cation for emergent colectomy or having proctitis,
Crohn’s disease, active infection, or usual contraindica-
tion to cyclosporine, infliximab, and thiopurine were
excluded. Results of the initial study have been previ-
ously published in extenso, showing that treatment fail-
ure occurred in 60% patients given cyclosporine and
54% given infliximab.12
The institutional review board at each center
approved the protocol, and all patients provided written
informed consent.
For assessment of endoscopic disease activity, 4
flexible sigmoidoscopies planned in the study protocol
were performed at baseline and at days 7, 42, and 98 in
patients still in the study. Examinations were locally read
and not recorded.
All patients enrolled into the CYSIF trial were
included in the endoscopic post hoc analysis if they
achieved steroid-free clinical remission at day 98,lsinki from ClinicalKey.com by Elsevier on August 02, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
What You Need to Know
Background
Endoscopic remission is a goal of treatment for ul-
cerative colitis. However, there have been few
endoscopic analyses of patients admitted to the
hospital with steroid-refractory acute severe ulcer-
ative colitis.
Findings
Endoscopic remission of acute severe ulcerative co-
litis requires approximately 3 months. It starts with
remission of bleeding, followed by healing of ulcer-
ations and erosions, and then by restoration of the
vascular pattern. A higher proportion of patients
who received second-line therapy with infliximab
achieved endoscopic remission than with
cyclosporine.
Implications for patient care
Patients should not be assessed too early by flexible
sigmoidoscopy—many features of acute severe ul-
cerative colitis require 3 months to heal. Infliximab
provides a higher endoscopic remission rate than
cyclosporine at 3 months.
1182 Laharie et al Clinical Gastroenterology and Hepatology Vol. 19, No. 6defined as total Mayo score at 2 or less with a Mayo
endoscopic subscore at 1 or less, or if they had steroid-
free Mayo endoscopic subscore at 2 and all other sub-
scores at 1 or less at day 98 without new treatment
initiated at day 98. Patients who experienced a relapse or
any severe adverse event leading to treatment modifi-
cation or interruption between day 7 and day 98 have
been excluded.
Endoscopic Findings
For each endoscopic assessment, the following pre-
specified endoscopic lesions were recorded per
segment (rectum and sigmoid colon) on a standardized
form: erythema (absent, mild, moderate, frank), fria-
bility (absent, mild, moderate, marked), granularity
(absent, present), erosion (absent, rare, intermediate,
numerous), superficial ulceration (absent, rare, inter-
mediate, numerous), and deep ulceration (absent, rare,
intermediate, numerous), including well-like ulceration,
mucosal detachment, and mucosal abrasion (absent,
present), pseudopolyp (absent, present). The Mayo
endoscopic subscore was reported from the standard-
ized form. As UCEIS has been available since 2012, the
total score and its subscores—vascular pattern,
bleeding, and erosion/ulceration—were post hoc
calculated in each segment from endoscopic reports as
follows: vascular pattern was scored 0 when erythema
was normal, 1 when it was mild, and 2 when it was
moderate or frank; bleeding was scored as friability;
erosions or ulcerations was scored 0 when erosion and
ulceration were absent, 1 in presence of erosion but no
ulceration, 2 in presence of superficial ulceration but
not deep ulceration, and 3 in presence of deep ulcer-
ation. Global UCEIS and vascular pattern, bleeding, and
erosions or ulcerations subscores were calculated for
the whole examination as maximal values across
rectum and sigmoid segments.
Global endoscopic remission was defined as UCEIS at
0 and partial endoscopic remission as vascular pattern
subscore at 0 for vascular pattern, as bleeding subscore
at 0 for bleeding, and as erosions or ulcerations subscore
at 0 for ulceration or erosion.
Objectives
Objectives of the study were the following: (1) to
describe the time course of Mayo endoscopic subscore,
UCEIS, and UCEIS subscores globally and per treatment
group; (2) to compare endoscopic remission between the
3 UCEIS subscores at each time point globally and per
treatment group; (3) to compare the evolution of the
UCEIS erosions or ulcerations subscore between patients
having a subscore of 3 and those having a subscore of 2
at inclusion at each time point; (4) to compare global and
partial endoscopic remission between rectum and sig-
moid at each time point; and (5) to compare global andDownloaded for Anonymous User (n/a) at University of He
2021. For personal use only. No other uses without permisspartial endoscopic remission between patients treated
with infliximab and those receiving cyclosporine and at
each time point.
Statistics
Patient characteristics were described as number and
percentage and median (interquartile range [IQR]) for
qualitative and quantitative items, respectively. To
describe the Mayo endoscopic subscore, UCEIS, and UCEIS
subscores, number, mean  SD, and proportions of each
subscore value were used because median (IQR) was not
enough informative due to too numerous ties. Partial
endoscopic remission rates were compared between
UCEIS subscores at each time point through paired chi-
square tests. Global and partial endoscopic remission
rates were compared similarly between rectum and sig-
moid segments. UCEIS and UCEIS subscores were
compared at each time point between both treatment
groups, as endoscopic remission rates through chi-square
test or as absolute levels through Mann-Whitney test.
According to the numerous tests performed, signifi-
cance was achieved for a P value <.005.
Results
Study Population
From the 115 patients randomized in the CYSIF trial,
55 have been included in the present endoscopic analysis
(29 received infliximab and 26 cyclosporine) becauselsinki from ClinicalKey.com by Elsevier on August 02, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 1.Main Patients’ Characteristics and Endoscopic Findings at Baseline
Characteristic All (N ¼ 55) Infliximab (n ¼ 29) Cyclosporine (n ¼ 26)
Female 30 (55) 15 (52) 15 (58)
Age, y 35 (27–48) 33 (26–50) 37 (27–45)
Disease duration, y 2.1 (0.2–7.0) 1.5 (0.2–4.9) 2.8 (0.6–7.8)
Disease location E3 34 (62) 18 (62) 16 (62)
Lichtiger score 12 (11–13) 12 (12–14) 11 (11–13)a
11 21 (38) 6 (21) 15 (58)
12–13 22 (40) 13 (45) 9 (35)a
14 12 (22) 10 (34) 2 (8)
Hemoglobin, g/dL 10.4 (9.2–11.8) 11.4 (9.5–12.1)b 9.7 (8.9–10.7)c
CRP, mg/L 41 (24–70) 46 (31–73) 28 (18–58)c
Albumin, g/L 28 (23–31) 24 (22–30)d 28 (27–31)
Mayo endoscopic subscore 3.0  0.1 3.0  0.2 3.0  0.0
Mayo endoscopic subscore 3 53 (96) 29 (100) 24 (92)
UCEIS 7.1  1.2 7.0  1.1 7.1  1.3
Vascular pattern UCEIS subscore
Mean  SD 2.0  0.0 2.0  0.0 2.0  0.0
Subscores 0/1/2 0/0/55 0/0/29 0/0/26
Bleeding UCEIS subscore
Mean  SD 2.3  0.9 2.2  1.0 2.3  0.9
Subscores 0/1/2/3 2/12/9/32 1/8/3/17 1/4/6/15
Erosion/ulceration UCEIS subscore
Mean  SD 2.8  0.5 2.8  0.4 2.7  0.6
Subscores 0/1/2/3 0/2/9/44 0/0/6/23 0/2/3/21
Values are n (%), median (interquartile range), or mean  SD, unless otherwise indicated.
Ulcerative colitis location according to the Montreal classification (E1: n ¼ 0).
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Characteristics of these 55 patients were similar
regarding age, sex, disease extension, median Lichtiger
score, and median C-reactive protein level with those of
the 60 randomized patients who were excluded from the
present analysis.
Main patients’ characteristics and endoscopic findings
at baseline are presented per treatment arm in Table 1.
Briefly, 30 (55%) were women with a median age of 35
(IQR, 27–48) years and a median disease duration since
diagnosis of 2.1 (IQR, 0.2–7.0) years; 14 (25%) patients
were admitted for first attack of ulcerative colitis. At
inclusion, patients had received intravenous steroids
during 8 (IQR, 6–9) days; they had median Lichtiger
score of 12 (IQR, 11–13).
Regarding endoscopic findings at baseline, all except 2
patients had Mayo endoscopic subscore of 3 and 49 (89%)
patients had UCEIS of 6 ormore. Regarding UCEIS subscores
at baseline, 55 (100%) patients had a vascular pattern sub-
score of 2, 41 (75%) a bleeding subscore of 2–3, and 53
(96%) an erosions or ulcerations subscore of 2–3.Downloaded for Anonymous User (n/a) at University of He
2021. For personal use only. No other uses without permissEvolution of Endoscopic Lesions
UCEIS and Mayo endoscopic subscores are described
in Figure 1, with UCEIS subscores in figure 2.
In the whole cohort, endoscopic remission defined by
UCEIS of 0 was achieved in 1 (n ¼ 55, 2%) patient at day
7, 13 (n ¼ 54, 24%) at day 42, and 25 (n ¼ 50, 50%) at
day 98. The endoscopic remission rate for vascular
pattern was lower than the endoscopic remission rates
for bleeding, but not for erosions or ulcerations, at day 7
(20% and 5%; n ¼ 55; P ¼ .004 and P ¼ 1.00, respec-
tively). The endoscopic remission rate for vascular
pattern was lower than the endoscopic remission rates
for bleeding and for erosions or ulcerations at day 42
(62% and 65%; n ¼ 54; P < .001 for both) and at day 98
(78% and 92%; n ¼ 50; P ¼ .007 and P < .001,
respectively) (Figure 3). As described in Supplementary
Figure 1, these results were mainly observed among
cyclosporine treated patients, whereas the subscore
remission rates appeared to evolve in a more parallel
way in patients on infliximab.lsinki from ClinicalKey.com by Elsevier on August 02, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Figure 1. Description of the UCEIS scores (top) and Mayo endoscopic subscores (bottom) at days 7 (n ¼ 55), 42 (n ¼ 54), and
98 (n ¼ 50) in patients admitted for a steroid-refractory acute severe ulcerative colitis who achieved clinical remission 98 days
after receiving second-line medical therapy: number of patients for each level and mean  SD.
1184 Laharie et al Clinical Gastroenterology and Hepatology Vol. 19, No. 6When comparing patients having erosions or ulcera-
tions subscore of 3 with patients having a erosions or
ulcerations subscore of 2 at inclusion, proportions of
patients achieving an erosions or ulcerations subscore of
0 were 0% and 22% (n ¼ 44 and 9) at day 7 (P ¼ .03),
58% and 89% (n ¼ 43 and 9) at day 42 (P ¼ .13), and
90% and 100% (n ¼ 39 and 9) at day 98 (P ¼ 1.00),
respectively.
Evolution of Endoscopic Lesions According to
Bowel Segment
There was no observed difference in endoscopic
remission rates between sigmoid and rectum at each
time point whatever the assessment used, UCEIS, or
UCEIS subscores (Supplementary Table 1).
Evolution of Endoscopic Lesions According to
Medication
Mayo endoscopic subscore, UCEIS, and UCEIS sub-
scores are described according to treatment in
Supplementary Figures 2 and 3.
Endoscopic remission rates with infliximab and
cyclosporine were 3% and 0% (n ¼ 29 and 26; P ¼ .34)
at day 7, 28% and 20% (n ¼ 29 and 25; P ¼ .52) at dayDownloaded for Anonymous User (n/a) at University of He
2021. For personal use only. No other uses without permiss42 and, 73% and 25% (n ¼ 26 and 24; P < .001) at day
98, respectively (Figure 4). Median UCEIS was signifi-
cantly lower in patients treated with infliximab than in
those who received cyclosporine only at day 98 (P ¼
.002; P ¼ .45 at day 7 and P ¼ .64 at day 42).
Regarding UCEIS subscores in patients treated by
infliximab and cyclosporine, endoscopic remission rates
at day 98 were 81% and 29% for vascular pattern (P ¼
.002), 88% and 67% for bleeding (P ¼ .06), 88%% and
96% for erosions or ulcerations (P ¼ .34), suggesting
that the observed difference on UCEIS between inflix-
imab- and cyclosporine-treated patients was mainly due
to a difference in vascular pattern subscore
(Supplementary Figure 4).
Discussion
In a prospective cohort of patients admitted for
steroid-refractory acute severe ulcerative colitis
responding to a second-line medical therapy, we
observed that the process of endoscopic response
in patients started from day 7 with absence of bleeding,
and then followed by ulceration healing and by resto-
ration of the vascular pattern, without discrepancies
between sigmoid and rectum. We also observed
that endoscopic remission rate at day 98 was higherlsinki from ClinicalKey.com by Elsevier on August 02, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Figure 2. Description of the UCEIS subscores at days 7 (n ¼ 55), 42 (n ¼ 54), and 98 (n ¼ 50) in patients admitted for a steroid-
refractory acute severe ulcerative colitis who achieved clinical remission 98 days after receiving second-line medical therapy:
number of patients for each level and mean  SD.
June 2021 Endoscopic Evolution of Acute Severe Ulcerative Colitis 1185in patients treated with infliximab than with
cyclosporine.
Controlled trials assessing the efficacy of biologic
agents in refractory ulcerative colitis, evaluated endo-
scopic remission - defined as Mayo endoscopic subscore
of 0–1—at the end of the induction period.13–19 How-
ever, data on the evolution of endoscopic lesions from
baseline to this endpoint is scarce. Drug-related factors,
such as its mode of action or speed of onset, and disease-
related factors, like endoscopic severity at baseline and
segmental location between colon and rectum, may in-
fluence the evolution of endoscopic healing in ulcerative
colitis. This granularity of data cannot be captured byDownloaded for Anonymous User (n/a) at University of He
2021. For personal use only. No other uses without permisssequential fecal calprotectin measurements and requires
repeated endoscopic assessments. We present here one
of the first study conducted in ulcerative colitis that
closely monitored endoscopic response by 4 flexible
sigmoidoscopies within 14 weeks. The optimal time
point for assessing mucosal healing in ulcerative colitis
remains arbitrary, from 6 to 12 weeks in controlled tri-
als, and depends on medication given. Our data suggest
leaving sufficient time for healing to occur and to do not
look at it too early in patients who started anti-tumor
necrosis factor or cyclosporine.
We observed that bleeding and ulcerations improved
within 6 weeks in two-thirds of patients, while thelsinki from ClinicalKey.com by Elsevier on August 02, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Figure 3. Evolution of
vascular pattern, bleeding,
and erosions or ulcera-
tions UCEIS subscores at
day 7 (n ¼ 55), 42 (n ¼ 54),
and 98 (n ¼ 50). Statistical
significance was defined
as P < .005 due to the
numerous comparisons
performed (P value in
bold).
1186 Laharie et al Clinical Gastroenterology and Hepatology Vol. 19, No. 6recovery of normal vascular pattern took longer and was
only achieved in half of patients at day 98. It could be
speculated that histological remission would be the next
step. Unfortunately, no biopsy samples were collected in
our cohort.
Two randomized controlled trials have compared
infliximab with cyclosporine in acute severe ulcerative
colitis showing no difference on short and long-term
outcomes between both drugs.12,20,21 However, in this
ancillary study from the CYSIF trial, infliximab induced a
significantly higher proportion of endoscopic remission
(ie, Mayo endoscopic subscore or UCEIS 0) than did
cyclosporine. This result was confirmed when comparing
median UCEIS at day 98 while responders to infliximab
had higher median Lichtiger score and C-reactive protein
level at baseline than responders to cyclosporine. Such a
finding may have an impact on subsequent disease
course as several studies have shown that patients with aFigure 4. Rates of endo-
scopic remission (UCEIS
at 0) in patients admitted
for a steroid-refractory
acute severe ulcerative
colitis who achieved clin-




at day 7 (n ¼ 29 and 26),
day 42 (n ¼ 29 and 25),
and day 98 (n ¼ 26 and
24). Statistical significance
was defined as P < .005
due to the numerous
comparisons performed (P
value in bold).
Downloaded for Anonymous User (n/a) at University of He
2021. For personal use only. No other uses without permissremnant mild endoscopic inflammation experience more
relapse and surgery than those who achieved mucosal
healing.22–24 Indeed, 46% of patients initially treated
with cyclosporine subsequently received infliximab
during the first year of follow-up in our cohort.20
Beyond traditional features observed in active ulcer-
ative colitis, acute severe attacks may be associated in
33%–72% to more severe endoscopic lesions, consisting
of deep ulcerations, well-like ulcerations, or mucosal
detachment mostly found in the rectum or the sigmoid
colon.25–29 Conversely to prior endoscopic scores, severe
endoscopic lesions have been implemented into the
UCEIS corresponding to the erosions or ulcerations
subscore at 3 defined as “deeper excavated defects in the
mucosa, with a slightly raised edge.”7 Some retrospec-
tives series have observed an association between these
lesions and higher colectomy rates or infliximab fecal
excretion.27,28,30 However, prospective studies have notlsinki from ClinicalKey.com by Elsevier on August 02, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
June 2021 Endoscopic Evolution of Acute Severe Ulcerative Colitis 1187yet confirmed this relationship. Similar to Jarnerot
et al,26 who reported the first placebo-controlled trial
conducted with infliximab in acute severe ulcerative
colitis, baseline severe endoscopic lesions were not
predictive of treatment failure in multivariate analysis in
our trial.12 Moreover, we observed in the present study
that patients with the UCEIS erosions or ulcerations
subscore of 2 and 3 at inclusion have the same evolution
for ulceration healing after day 7, even if these results
had to be taken with caution due to the evident lack of
power. Overall, the significance of severe endoscopic le-
sions remains poorly understood and requires further
studies.
The present study acknowledges some limitations
such as UCEIS post hoc calculation, endoscopic as-
sessments not centrally read and lack of histologic
assessment. Last, as in most exploratory studies,
numerous tests were performed. Nevertheless, we
defined statistical significance as when the P value
was <.005.
In order to describe evolution of endoscopic lesions
in patients responding to a second-line medical therapy,
patients included into the present analysis were pro-
spectively followed within a randomized clinical trial
and closely monitored by 4 repeated flexible sigmoid-
oscopies using a standardized form describing pre-
specified endoscopic lesions per segment with few
missing data.
In conclusion, endoscopic remission of acute severe
ulcerative colitis takes approximately 3 months. It starts
with bleeding remission at day 7, followed by ulceration
or erosion healing and then by restoration of the vascular
pattern that is coming back to normal in half of patients
at 3 months. In clinical practice, patients should not be
assessed too early by flexible sigmoidoscopy. The higher
rate of patients in endoscopic remission after induction
with infliximab than cyclosporine may be associated with
less subsequent disease flare, suggesting that deep
remission would be a desirable goal in acute severe ul-
cerative colitis.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
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Supplementary
Figure 1. Rates of Ulcera-
tive Colitis Endoscopic In-
dex of Severity (UCEIS)
subscores 0 in patients
admitted for a steroid-
refractory acute severe ul-
cerative colitis who ach-
ieved clinical remission 98
days according to treat-
ment (infliximab or cyclo-
sporine), at day 7 (n ¼ 29
and 26), day 42 (n¼ 29 and
25), and day 98 (n¼ 26 and
24). B, bleeding, U, ero-
sions or ulcerations; VP,
vascular pattern.
Supplementary Figure 2. Description of the UCEIS scores (top) and Mayo endoscopic subscores (bottom) at days 0 (n ¼ 55),
7 (n ¼ 55), 42 (n ¼ 54), and 98 (n ¼ 50) according to medication in patients admitted for a steroid-refractory acute severe
ulcerative colitis who achieved clinical remission 98 days after receiving second-line medical therapy: number of patients for
each level and mean  SD.
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Supplementary Figure 3. Description of the UCEIS subscores at days 0 (n ¼ 55), 7 (n ¼ 55), 42 (n ¼ 54) and 98 (n ¼ 50)
according to medication in patients admitted for a steroid-refractory acute severe ulcerative colitis who achieved clinical
remission 98 days after receiving second-line medical therapy: number of patients for each level and mean  SD.
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Supplementary
Figure 4. Rates of UCEIS
subscores 0 compared
between patients treated
with infliximab or cyclo-
sporine at day 7 (n ¼ 29
and 26), day 42 (n¼ 29 and
25), and day 98 (n¼ 26 and
24).
Supplementary Table 1.Global and Partial Endoscopic
Remission Rates at Days 7, 42, and
98 in the Whole Population (N ¼ 55)
According to Bowel Segment
Rectum Sigmoid P Value
Day 7
UCEIS 0 (n ¼ 54) 3 (6) 2 (4) 1.00
Vascular pattern 0 (n ¼ 55) 3 (5) 4 (7) 1.00
Bleeding 0 (n ¼ 55) 19 (35) 15 (27) .39
Erosion/ulcerations 0 (n ¼ 54) 12 (22) 5 (9) .065
Day 42
UCEIS 0 (n ¼ 50) 18 (36) 16 (32) .77
Vascular pattern 0 (n ¼ 53) 23 (43) 22 (42) 1.00
Bleeding 0 (n ¼ 53) 37 (70) 40 (75) .51
Erosion/ulcerations 0 (n ¼ 50) 37 (74) 33 (66) .22
Day 98
UCEIS 0 (n ¼ 47) 27 (57) 34 (72) .092
Vascular pattern 0 (n ¼ 50) 31 (62) 38 (76) .092
Bleeding 0 (n ¼ 50) 41 (82) 41 (82) 1.00
Erosion/ulcerations 0 (n ¼ 47) 43 (91) 45 (96) .50
Values are n (%).
UCEIS, Ulcerative Colitis Endoscopic Index of Severity.
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Supplementary Table 2.Median Rectal Bleeding and Stool Frequency Scores and CRP Levels at day 7, 42, and 98 Among
the 55 Patients Who Responded to Infliximab or Cyclosporine After Intravenous Steroid Failure
Infliximab (n ¼ 29) Cyclosporine (n ¼ 26) P Value
Rectal bleeding score
Baseline 2.3  0.8 2.8  0.9 .75
Day 7 0.3  0.7 0.7  0.9 .07
Day 42 0.1  0.4 0.2  0.6 .55
Day 98 0.0 0.1  0.3 .06
Stool frequency score
Baseline 2.9  0.3 2.6  0.6 .05
Day 7 1.1  0.9 1.0  0.8 .81
Day 42 0.3  0.7 0.2  0.4 .82
Day 98 0.2  0.4 0.1  0.3 .55
CRP level
Baseline 46 (31–73) 28 (18–50) .05
Day 7 4 (3–17) 8 (4–19) .33
Day 42 2.5 (1–7) 2.5 (1–4) .70
Day 98 2.5 (1–5) 2.5 (1–4) .58
NOTE. Values are mean  SD or median (interquartile range).
CRP, C-reactive protein.
1188.e4 Laharie et al Clinical Gastroenterology and Hepatology Vol. 19, No. 6
Downloaded for Anonymous User (n/a) at University of Helsinki from ClinicalKey.com by Elsevier on August 02, 
2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.
